Quick Takeaways
- BML Investment Partners, L.P. filed SCHEDULE 13D/A for AN2 Therapeutics, Inc. Common Stock, par value $0.00001 per share (ANTX).
- Disclosed ownership: 11%.
- Date of event: 28 May 2025.
BML Investment Partners, L.P. - 28 May 2025 SCHEDULE 13D/A Report for AN2 Therapeutics, Inc. Common Stock, par value $0.00001 per share (ANTX)
- Filing Manager
- BML Investment Partners, L.P.
- Reporting Manager
- BML Investment Partners, L.P.
- Symbol
- ANTX
- Shares outstanding
- 30,069,374 shares
- Disclosed Ownership
- 3,217,423 shares
- Ownership
- 11%
- Form type
- SCHEDULE 13D/A
- Filing time
- 30 May 2025, 17:46:45 UTC
- Date of event
- 28 May 2025
- Previous filing
- 07 May 2025
- Next filing
- 18 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BML Investment Partners, L.P. disclosed 11% ownership in AN2 Therapeutics, Inc. Common Stock, par value $0.00001 per share (ANTX) on 28 May 2025."
What Changed
- Previous schedule filing date: 07 May 2025.
- Current filing was accepted on 30 May 2025, 17:46.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BML Investment Partners, L.P. | 11% | 3,217,423 | 0 | 3,217,423 | Braden M Leonard | Braden M Leonard - Managing Member of BML Capital Management, LLC | 0001373604 |